Merck & Co., Inc. (MRK) Release: New 96-Week ACTG Study Results Presented At CROI 2014; First Large Study Comparing ISENTRESS® (Raltegravir) Regimen To Two Protease Inhibitor Regimens In Previously Untreated Adults With HIV-1
3/5/2014 11:00:18 AM
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-naïve patients – one containing Merck’s twice-daily ISENTRESS® (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time to virologic failure (VF), the study’s co-primary endpoint. On the other co-primary endpoint of failure due to tolerability, the ISENTRESS and darunavir/r regimens were superior to the atazanavir/r regimen. In addition, on the key secondary endpoint of the combination of VF and tolerability failure (TF), the regimen with ISENTRESS was superior to both of the protease inhibitor regimens. The results of this ACTG study were presented in an oral session today at the 21st Conference on Retroviruses and Opportunistic Infections (CROI).
Help employers find you! Check out all the jobs and post your resume.
comments powered by